The business combination between Humacyte and the special purpose acquisition company Alpha Healthcare Acquisition Corp. cleared one of its final hurdles today: shareholder approval. The deal closes later this week.
Read More
Alpha Healthcare Acquisition Corp. has announced the nominees who will stand for election and reelection to its Board of Directors during the Aug. 24, AHAC special shareholder’s meeting to vote on the proposed business combination with Humacyte. Here are the details.
Read More
Durham’s Humacyte is expanding a collaboration with a company which is an investor as Humacyte prepares to go public via a SPAC.
Read More
Bioengineering startup Humacyte has secured $50 million in debt financing from Silicon Valley Bank as it prepares to go public through a SPAC merger with Alpha Healthcare Acquisition Corp.
Read More
Special Purpose Acquisition Companies (SPACs), the hottest financial craze to hit Wall Street for taking companies public, is hitting the Triangle with news early Wednesday that Durham-based life science firm Humacyte has chosen the SPAC vehicle for its stock offering.
Read More
Dr. Laura Niklason is returning in a full-time role to Humacyte, the company focusing o bioengineered human tissue that she founded 16 years ago, as its chief executive officer. She’s giving up a position at Yale University. Here are the details.
Read More
Here’s our latest roundup of the latest headlines from Triangle area tech and life science companies.
Read More
Humacyte, a regenerative medicine company based in Durham, has demonstrated that its human acellular vessels (HAVs) repopulate with a patient’s own cells to form a living vascular tissue.
Read More
Local bioscience companies snagged four of the five awards given for best-in-class deals in 2018 at the BIO Investor and Partnering Forum in Atlanta this month.
Read More
